Xarelto (Rivaroxaban) Bleeding US
closedCompany record in this matter
Bristol-Myers Squibb (Xarelto, with Janssen) was a named defendant in MDL 2592 (Xarelto bleeding, E.D. La.). The FDA issued a 2013 safety communication on serious bleeding (per FDA); BMS and Janssen reached a $775 million settlement in 2020 (per public reports).
Full case record
Court details, case count history, key dates, filings, sources and FAQ are on the main case page:
Frequently asked questions
Is Bristol-Myers Squibb being sued in Xarelto (Rivaroxaban) Bleeding?
Yes — Bristol-Myers Squibb is listed among the companies in this matter. Status as of 2026-09-01: closed. The full case record has the court, docket and all key dates.
What is the status of Xarelto (Rivaroxaban) Bleeding?
As of 2026-09-01, the matter is in the “closed” stage with 4,000 cases on the record. Every change is logged in the case record's updates section with its source.
Where can I see the full record for Xarelto (Rivaroxaban) Bleeding?
The main case page has the full record: court and judge, case count history, key dates, filings, settlement amounts where published, and sources. It is linked at the top of this section.
About the company
Regulatory history, violations, and every tracked case for Bristol-Myers Squibb →
Think this matters to you?
This is reference material — not legal advice. Start a free case review.
Start free case review →